OzAurum Resources kicks off grade control drilling at Mulgabbie North
OzAurum Resources is ramping up development of the Mulgabbie North gold project in Western Australia with new drilling underway.
Market Cap $109.8M
!
Corporate Spotlight
Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug development company focused on delivering new therapies to address unmet medical needs.
View the full Corporate Spotlight
IPPS Blockbuster Potential and 50% Phase 3
Last update - 16.10pm 13/03/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 25.0¢ | Day High | 27.0¢ | Day Low | 24.5¢ | |||
| Daily Volume | 894342 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 26.0¢ | 4999 | 0 | 27.0¢ | 22380 | |
Directors & Senior Management
| Ms. Abby Macnish Niven | Company Secretary & CFO |
| Mr. Amos Meltzer | Independent & Non-Executive Director |
| Ms. Beverley Huttmann | Commercial Head |
| Dr. Donna L. Skerrett | Chief Medical Officer |
| Mr. Matthew James Fry | Independent Non-Executive Director |
| Dr. Michael Imperiale | Global Head of Drug Safety & MPS |
| Dr. Mukesh Ahuja | Global Clinical Head of OA |
| Mr. Paul John Rennie | Founder, MD & Executive Chairman |
| Dr. Ravi Krishnan | Chief Scientific Officer |
| Mr. Simon White | Director of Investor Relations |
Data source: ADVFN
